# Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

> **NCT05700721** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 120 (estimated)

## Conditions studied

- Brain Metastases

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Dostarlimab

## Key facts

- **NCT ID:** NCT05700721
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-02
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05700721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05700721, "Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT05700721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*